$1.21+0.00 (+0.42%)
Solesence, Inc., a science-driven company, provides engineered materials, formulation development, and commercial manufacturing services in the United States.
Solesence, Inc. in the Consumer Defensive sector is trading at $1.21. The stock is currently near its 52-week low of $0.78, remaining 40.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Solesence, Inc., a science-driven company, provides engineered materials, formulation development, and commercial manufacturing services in the United States. The company engages in the manufacture and supply of surface engineered zinc oxide and tita...
Kevin Cureton: Thank you, operator, and thank you to our investors, brand partners and teammates who are joining us today. To walk you through how we wrapped up 2025, I'll turn the call over to our CFO, Laura Riffner. Laura Riffner: Thank you, Kevin.
Solesence incurs a Q1 loss per share as shipment delays pressure revenues, even as gross margin improves and the company reaffirms its 2026 profitability targets.
Solesence Inc (SLSN) reports a revenue dip but remains optimistic about future growth through new technologies and improved operational strategies.
Moby summary of Solesence, Inc. Common Stock's Q1 2026 earnings call
Solésence reported improved gross margin in the first quarter despite lower revenue and a return to a net loss, as the company continued executing its Transform & Transcend strategic initiative. Key Investor TakeawaysSolésence (NASDAQ:SLSN) posted first-quarter revenue of $13.